Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 5
2011 11
2012 19
2013 25
2014 71
2015 100
2016 116
2017 142
2018 109
2019 96
2020 99
2021 20
Text availability
Article attribute
Article type
Publication date

Search Results

715 results
Results by year
Filters applied: . Clear all
Page 1
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. Lannutti BJ, et al. Blood. 2011 Jan 13;117(2):591-4. doi: 10.1182/blood-2010-03-275305. Epub 2010 Oct 19. Blood. 2011. PMID: 20959606 Free PMC article.
We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110delta small molecule inhibitor (half-maximal effective concentration [EC(50)] = 8nM). ...These effects have been observed acro …
We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective a …
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Castillo JJ, Furman M, Winer ES. Castillo JJ, et al. Expert Opin Investig Drugs. 2012 Jan;21(1):15-22. doi: 10.1517/13543784.2012.640318. Epub 2011 Nov 24. Expert Opin Investig Drugs. 2012. PMID: 22112004 Review.
EXPERT OPINION: CAL-101 is a novel drug that has shown preclinical activity against CLL, NHL, HL and PCM cells. There is early evidence of clinical efficacy in CLL and indolent NHL. Studies using CAL-101 alone or in combination are also ongoing in PCM, …
EXPERT OPINION: CAL-101 is a novel drug that has shown preclinical activity against CLL, NHL, HL and PCM cells. There is early …
[CAL-101,a novel agent of targeted therapy in hematological malignancies].
Li CJ, Zhang Q, Zhang YZ. Li CJ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):530-3. doi: 10.7534/j.issn.1009-2137.2014.02.049. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014. PMID: 24763037 Review. Chinese.
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. ...This review focuses on the target, m
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migr
Chronic lymphocytic leukaemia.
Hallek M, Shanafelt TD, Eichhorst B. Hallek M, et al. Lancet. 2018 Apr 14;391(10129):1524-1537. doi: 10.1016/S0140-6736(18)30422-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477250 Review.
The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. ...
The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard o …
Idelalisib.
Zirlik K, Veelken H. Zirlik K, et al. Recent Results Cancer Res. 2018;212:243-264. doi: 10.1007/978-3-319-91439-8_12. Recent Results Cancer Res. 2018. PMID: 30069634 Review.
Idelalisib (GS-1101, CAL-101, Zydelig()) is an orally bioavailable, small-molecule inhibitor of the delta isoform (p110delta) of the enzyme phosphoinositide 3-kinase (PI3K). ...Idelalisib is the first PI3K inhibitor approved by the US Food and Drug Adm
Idelalisib (GS-1101, CAL-101, Zydelig()) is an orally bioavailable, small-molecule inhibitor of the delta isoform (p110
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
Greenwell IB, Ip A, Cohen JB. Greenwell IB, et al. Oncology (Williston Park). 2017 Nov 15;31(11):821-8. Oncology (Williston Park). 2017. PMID: 29179250 Free article. Review.
The phosphatidylinositol 3-kinase (PI3K) pathway has attracted immense interest as a therapeutic target for cancer treatment. Idelalisib was the first PI3K inhibitor approved by the US Food and Drug Administration and is utilized in the treatment of relapsed/refractory chr …
The phosphatidylinositol 3-kinase (PI3K) pathway has attracted immense interest as a therapeutic target for cancer treatment. Idelalisib
B and T cell prolymphocytic leukaemia.
Cross M, Dearden C. Cross M, et al. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228. doi: 10.1016/j.beha.2019.06.001. Epub 2019 Jun 6. Best Pract Res Clin Haematol. 2019. PMID: 31585622 Review.
Targeting the PI3K pathway in cancer: are we making headway?
Janku F, Yap TA, Meric-Bernstam F. Janku F, et al. Nat Rev Clin Oncol. 2018 May;15(5):273-291. doi: 10.1038/nrclinonc.2018.28. Epub 2018 Mar 6. Nat Rev Clin Oncol. 2018. PMID: 29508857 Review.
Nevertheless, the mTOR inhibitors temsirolimus and everolimus and the PI3K inhibitors idelalisib and copanlisib have been approved by the FDA for clinical use in the treatment of a number of different cancers. ...
Nevertheless, the mTOR inhibitors temsirolimus and everolimus and the PI3K inhibitors idelalisib and copanlisib have been approved by …
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
Curigliano G, Shah RR. Curigliano G, et al. Drug Saf. 2019 Feb;42(2):247-262. doi: 10.1007/s40264-018-0778-4. Drug Saf. 2019. PMID: 30649751 Review.
Although many PI3K inhibitors have reached different stages of clinical development, only two (idelalisib and copanlisib) have been currently approved for use in the treatment of B cell lymphoma and leukaemias. ...
Although many PI3K inhibitors have reached different stages of clinical development, only two (idelalisib and copanlisib) have been c …
Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress.
Park GB, Hur DY, Kim D. Park GB, et al. Anticancer Res. 2015 May;35(5):2699-708. Anticancer Res. 2015. PMID: 25964548
Co-treatment with CAL-101 and celecoxib triggered the ER stress response and the down-regulation of BCL2 and BCL-XL. ...Levels of apoptosis signal-regulating kinase 1 (ASK1) were also increased after treatment with CAL-101 and celecoxib. CONCLUSION: Th …
Co-treatment with CAL-101 and celecoxib triggered the ER stress response and the down-regulation of BCL2 and BCL-XL. ...Levels …
715 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page